Now CE Marked: 1-month DAPT indication for High Bleeding Risk Patients
XIENCE 28 showed that XIENCE™ Stent with 1-month DAPT had no increase in ischemic events and a significantly lower rate of severe bleeding (BARC 3-5) compared with 6-month DAPT. These data were used to support the CE Mark for a 1-month DAPT indication in High Bleeding Risk Patients.
XIENCE™ Stent is proven safe with 1-month and 3-month DAPT in HBR patients.1
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.